Sign In
Buy CAMP
$3.96
-0.230 (-5.49%)
At Close: Jun 15, 2026
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 14'th Nov 2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
04:05pm, Thursday, 06'th Nov 2025
Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicolo
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
08:00am, Wednesday, 01'st Oct 2025
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 25'th Sep 2025
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
07:00am, Wednesday, 10'th Sep 2025
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $5
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
04:05pm, Thursday, 14'th Aug 2025
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targ
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
04:05pm, Tuesday, 13'th May 2025
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targe
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
04:05pm, Thursday, 27'th Mar 2025
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynam
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
08:00am, Tuesday, 18'th Mar 2025
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.
CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
10:39pm, Thursday, 13'th Mar 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
02:58pm, Thursday, 13'th Mar 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
CAMP4 to Participate in Upcoming Investor Conferences
08:00am, Thursday, 06'th Feb 2025
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antise
CalAmp Launches Okta Single Sign-On Integration to Strengthen Security and Streamline User Access Across Applications
06:48pm, Thursday, 30'th Jan 2025
CARLSBAD, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- CalAmp, a leading provider of telematics and connected intelligence solutions, is pleased to announce the integration of Okta Single Sign-On (SSO) a
